Share, Send, or Save

Our History

Alexion Timeline: A Commitment to Breakthrough Innovation

The years since Alexion was established in 1992 have been extraordinary. With courage and tenacity, we have explored the most complex scientific challenges to find answers for patients with rare diseases. What has made us successful in the past, and what will continue to make us successful in the future, is our shared purpose – serving patients with devastating diseases who have been overlooked. Here are some of the milestones that have marked our growth.

Company Milestone Product Milestone Awards and Recognition
 
  • 2017
    Alexion is named one of the World's Most Innovative Companies by Forbes consecutively from 2012 to 2017
    Soliris® (eculizumab) is approved in the EU for the treatment of patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. Marketing applications for Soliris for the treatment of patients with anti-AChR antibody-positive refractory gMG have been accepted for review in the U.S. and Japan
  • 2016
    Kanuma is approved as a treatment for patients with lysosomal acid lipase deficiency (LAL-D) in Japan
    Alexion receives 2016 Rare Impact Award from the National Organization for Rare Disorders (NORD) and is named as Industry Innovation Honoree for the Company’s work in bringing Strensiq and Kanuma to market
    Alexion receives orphan drug designation (ODD) for ALXN1007 for the treatment of graft-versus-host disease (GVHD) from the U.S. FDA and the European Commission (EC)
    Kanuma receives 2016 German Prix Galien Award in the Orphan Product category
    Science names Alexion as a Top Employer in both 2015 and 2016
    Alexion initiates two Phase 3 clinical trials of ALXN1210 in complement inhibitor treatment-naïve patients with PNH and aHUS, and receives ODD for ALXN1210 for the treatment of patients with PNH from the EC
  • 2015
    Strensiq® (asfotase alfa) is approved as a treatment for patients with hypophosphatasia (HPP) in the U.S., EU, Japan and Canada
    Kanuma® (sebelipase alfa) is approved as a treatment for patients with lysosomal acid lipase deficiency (LAL-D) in the U.S. and EU
    Alexion is named one of Fortune Magazine’s Fastest Growing Companies in 2011, 2012, 2014 and 2015
  • 2014
    Alexion expands its drug-discovery capabilities with a long-term strategic agreement with Moderna Therapeutics to develop messenger RNA (mRNA) Therapeutics™ for rare diseases
    Soliris receives orphan drug designation (ODD) for multiple potential indications:
    • Prevention of delayed graft function (DGF) in renal transplant patients from the FDA, and prevention of DGF after solid organ transplantation from the EMA
    • Treatment of refractory myasthenia gravis (MG) from the FDA and EMA
    Alexion initiates multinational registration trials of eculizumab as a potential treatment for patients with NMO, MG and DGF
    Alexion's Board of Directors appoints Leonard Bell, M.D., as Chairman of the Board
    Connecticut Magazine names Alexion one of the top workplaces in the state in both 2010 and 2014
  • 2013
    Asfotase alfa receives Breakthrough Therapy Designation from the FDA for the treatment of HPP, and cPMP (ALXN1101) receives Breakthrough Therapy Designation for the treatment of molybdenum cofactor deficiency (MoCD) Type A
    Soliris is approved as a treatment for patients with aHUS in Japan
    Soliris receives orphan drug designation (ODD) for the treatment of neuromyelitis optica (NMO) from the FDA and EMA
  • 2012
    Alexion acquires asfotase alfa, the first potential treatment for patients with hypophosphatasia (HPP)
    New England Journal of Medicine publishes data from Phase 2 study of asfotase alfa in
    life-threatening HPP
    Alexion is added to the S&P 500 Index of leading global companies
    Alexion presented with the Partners in Progress Award from the National Organization for Rare Diseases (NORD)
  • 2011
    The FDA and the EMA approve Soliris as the first and only treatment for adult and pediatric patients with aHUS
  • 2010
    Alexion’s Rhode Island manufacturing facility receives FDA approval to supply Soliris
    Alexion receives the Green Advocate Award from the Connecticut Green Building Council (CTGBC) for its global headquarters and research facilities in Cheshire, Connecticut
    U.S. Green Building Council (USGBC) twice recognizes Alexion with LEED Certification Awards for constructing, operating and maintaining interiors that meet the highest green building and performance standards
  • 2009
    Soliris receives the Prix Galien France Award for Drugs for Rare Diseases
    Alexion's Rhode Island manufacturing facility receives EU approval to supply Soliris
  • 2008
    Soliris is first used as a treatment for patients with atypical hemolytic uremic syndrome (aHUS) in France and Germany
    Soliris receives the Prix Galien USA Award for Best Biotechnology Product
  • 2007
    Soliris® (eculizumab) receives approval from the FDA and European Medicines Agency (EMA) as the first and only treatment for patients with PNH
    Alexion honored with the Corporate Leadership Award from the National Organization for Rare Disorders (NORD)
    Alexion earns the Award of Excellence from Connecticut United for Research Excellence (CURE)
  • 2006
  • 2005
    Second pivotal Phase 3 study of eculizumab in patients with PNH begins (SHEPHERD)
  • 2002-2004
    Pilot study with eculizumab commences in Leeds, England in paroxysmal nocturnal hemoglobinuria (PNH)
    New England Journal of Medicine publishes positive results from pilot study of eculizumab in 11 patients with PNH
    First pivotal Phase 3 study of eculizumab commences in patients with PNH (TRIUMPH)
  • 2000
  • 1996-1998
    First in-human clinical trial of eculizumab begins
  • 1992-1994
    C5 complement inhibitor development program commences